Head-to-head · Cost-Efficiency Index
Dollar Dad Club vs Ivy Rx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Dollar Dad Club
Shoppers willing to read past the homepage headline to the product page's actual terms in exchange for named, license-numbered prescribers.
Visit Dollar Dad ClubIvy Rx
Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms.
Visit Ivy RxThe verdict
Dollar Dad Club and Ivy Rx tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with Dollar Dad Club (ranked #98, a hair above #102) — Shoppers willing to read past the homepage headline to the product page's actual terms in exchange for named, license-numbered prescribers. But Ivy Rx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Dollar Dad Club.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Dollar Dad Club | Ivy Rx |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $129/mo (all doses, compounded) | $97/mo (microdose tier, promotional rate, compounded) |
| Tirzepatide / mo | $129/mo | $199/mo (brand Mounjaro, compounded) |
| Semaglutide / yr (modeled) | $1,548 | $1,164 |
| Tirzepatide / yr (modeled) | $1,548 | $2,388 |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Yes |
| Rank here | #98 | #102 |
Dollar Dad Club
69/100Where the value is
- Genuinely names individual licensed prescribers with license numbers by state (Dr. Jeffrey Shellenberger — CA #C160558, MA #290752, VT #042.0015585-COMP; Dr. Marc Serota — RI #MA17024), rarer transparency than most competitors in this batch
- Claims all-50-state coverage
- Both an injectable (semaglutide/tirzepatide, same price) and an oral semaglutide option are offered on one platform
The tradeoffs
- The homepage's headline prices do not reconcile with the product pages' own numbers: '$89/month' injectable matches no total shown anywhere (real totals are $599-$899 for a 6-month plan), and '$149/month' oral is a 3-month-prepay, promo-code, lowest-dose-only rate whose true 1-month price at that dose is $449 — three times the headline
- No compounding pharmacy named, only generic 'leading U.S.-based compounding pharmacies'
Ivy Rx
69/100Where the value is
- Genuinely low entry price on the semaglutide microdose tier ($77/mo)
- HSA/FSA eligible with itemized receipts for reimbursement
- Legal entity is named (Ivy RX PLLC), which many competitors in this batch do not disclose
The tradeoffs
- The standard semaglutide price is shown as a struck-through discount ('$197 $97') with no label clarifying whether $97 is a standing rate or a temporary promo
- The advertised $199/mo tirzepatide rate requires a 12-month upfront lump-sum payment, not month-to-month billing, and a separate unexplained $1,399 vial price appears on the same page
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.